Literature DB >> 32187525

Leveraging the Gut to Treat Metabolic Disease.

Ruth E Gimeno1, Daniel A Briere1, Randy J Seeley2.   

Abstract

25 years ago, the future of treating obesity and diabetes focused on end organs known to be involved in energy balance and glucose regulation, including the brain, muscle, adipose tissue, and pancreas. Today, the most effective therapies are focused around the gut. This includes surgical options, such as vertical sleeve gastrectomy and Roux-en-Y gastric bypass, that can produce sustained weight loss and diabetes remission but also extends to pharmacological treatments that simulate or amplify various signals that come from the gut. The purpose of this Review is to discuss the wealth of approaches currently under development that seek to further leverage the gut as a source of novel therapeutic opportunities with the hope that we can achieve the effects of surgical interventions with less invasive and more scalable solutions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bariatric surgery; gastrointestinal tract; gut peptides; obesity; type 2 diabetes

Year:  2020        PMID: 32187525      PMCID: PMC7184629          DOI: 10.1016/j.cmet.2020.02.014

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  248 in total

1.  A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates.

Authors:  Shamina M Rangwala; Katharine D'Aquino; Yue-Mei Zhang; Lindsay Bader; Wilson Edwards; Songmao Zheng; Annette Eckardt; Ann Lacombe; Rebecca Pick; Veronica Moreno; Lijuan Kang; Wenying Jian; Eric Arnoult; Martin Case; Celia Jenkinson; Ellen Chi; Ronald V Swanson; Paul Kievit; Kevin Grove; Mark Macielag; Mark D Erion; Ranabir SinhaRoy; James N Leonard
Journal:  Cell Metab       Date:  2019-02-14       Impact factor: 27.287

2.  Differential Changes in Gut Microbiota After Gastric Bypass and Sleeve Gastrectomy Bariatric Surgery Vary According to Diabetes Remission.

Authors:  Rinki Murphy; Peter Tsai; Mia Jüllig; Amy Liu; Lindsay Plank; Michael Booth
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

3.  Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.

Authors:  Jonathan E Wilson; Ravi Kurukulasuriya; Christopher Sinz; Matthew Lombardo; Kate Bender; Dann Parker; Edward C Sherer; Melissa Costa; Karen Dingley; Xiaofang Li; Stanley Mitelman; Sharon Tong; Randal Bugianesi; Anka Ehrhardt; Birgit Priest; Kevin Ratliff; Feroze Ujjainwalla; Ravi Nargund; William K Hagmann; Scott Edmondson
Journal:  Bioorg Med Chem Lett       Date:  2016-06-15       Impact factor: 2.823

4.  Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.

Authors:  Narihiro Toda; Xiaolin Hao; Yasuyuki Ogawa; Kozo Oda; Ming Yu; Zice Fu; Yi Chen; Yongjae Kim; Mike Lizarzaburu; Sarah Lively; Shauna Lawlis; Michiko Murakoshi; Futoshi Nara; Nobuaki Watanabe; Jeff D Reagan; Hui Tian; Angela Fu; Alykhan Motani; Qingxiang Liu; Yi-Jyun Lin; Run Zhuang; Yumei Xiong; Peter Fan; Julio Medina; Leping Li; Masanori Izumi; Ryo Okuyama; Satoshi Shibuya
Journal:  ACS Med Chem Lett       Date:  2013-06-17       Impact factor: 4.345

Review 5.  GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.

Authors:  Cheng Chen; He Li; Ya-Qiu Long
Journal:  Bioorg Med Chem Lett       Date:  2016-10-26       Impact factor: 2.823

Review 6.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

7.  Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility.

Authors:  J M Lundberg; K Tatemoto; L Terenius; P M Hellström; V Mutt; T Hökfelt; B Hamberger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

8.  PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet.

Authors:  Anita M van den Hoek; Annemieke C Heijboer; Eleonora P M Corssmit; Peter J Voshol; Johannes A Romijn; Louis M Havekes; Hanno Pijl
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

9.  Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.

Authors:  Robert R Henry; Theodore P Ciaraldi; Debra Armstrong; Paivi Burke; Monica Ligueros-Saylan; Sunder Mudaliar
Journal:  J Clin Endocrinol Metab       Date:  2013-06-03       Impact factor: 5.958

10.  GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function.

Authors:  Hua V Lin; Jingru Wang; Jie Wang; Weiji Li; Xuesong Wang; James T Alston; Melissa K Thomas; Daniel A Briere; Samreen K Syed; Alexander M Efanov
Journal:  Mol Metab       Date:  2018-02-23       Impact factor: 7.422

View more
  17 in total

1.  GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.

Authors:  Ricardo J Samms; Michael E Christe; Kyla Al Collins; Valentina Pirro; Brian A Droz; Adrienne K Holland; Jessica L Friedrich; Samantha Wojnicki; Debra L Konkol; Richard Cosgrove; Ellen Ps Conceição Furber; Xiaoping Ruan; Libbey S O'Farrell; Annie M Long; Mridula Dogra; Jill A Willency; Yanzhu Lin; Liyun Ding; Christine C Cheng; Over Cabrera; Daniel A Briere; Jorge Alsina-Fernandez; Ruth E Gimeno; Julie S Moyers; Tamer Coskun; Matthew P Coghlan; Kyle W Sloop; William C Roell
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

2.  Similar Gut Hormone Secretions Two Years After One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass: a Pilot Study.

Authors:  Claire Carette; Johanne Le Beyec; David De Bandt; Claire Rives-Lange; Yvann Frigout; Damien Bergerot; Anne Blanchard; Maude Le Gall; Jean-Marc Lacorte; Jean-Marc Chevallier; Sébastien Czernichow; Tigran Poghosyan
Journal:  Obes Surg       Date:  2022-01-07       Impact factor: 4.129

3.  Vertical sleeve gastrectomy induces enteroendocrine cell differentiation of intestinal stem cells through bile acid signaling.

Authors:  Ki-Suk Kim; Bailey Ce Peck; Yu-Han Hung; Kieran Koch-Laskowski; Landon Wood; Priya H Dedhia; Jason R Spence; Randy J Seeley; Praveen Sethupathy; Darleen A Sandoval
Journal:  JCI Insight       Date:  2022-06-08

Review 4.  Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?

Authors:  Ellen Conceição-Furber; Tamer Coskun; Kyle W Sloop; Ricardo J Samms
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-25       Impact factor: 6.055

Review 5.  A Role for GLP-1 in Treating Hyperphagia and Obesity.

Authors:  Harvey J Grill
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 6.  Gut-brain communication and obesity: understanding functions of the vagus nerve.

Authors:  Hans-Rudolf Berthoud; Vance L Albaugh; Winfried L Neuhuber
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 7.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330

Review 8.  The Microbiota and the Gut-Brain Axis in Controlling Food Intake and Energy Homeostasis.

Authors:  Marina Romaní-Pérez; Clara Bullich-Vilarrubias; Inmaculada López-Almela; Rebeca Liébana-García; Marta Olivares; Yolanda Sanz
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

9.  Enteroendocrine Dynamics - New Tools Reveal Hormonal Plasticity in the Gut.

Authors:  Joep Beumer; Helmuth Gehart; Hans Clevers
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

Review 10.  Stabilizing Cellular Barriers: Raising the Shields Against COVID-19.

Authors:  Julia Hanchard; Coral M Capó-Vélez; Kai Deusch; Darcy Lidington; Steffen-Sebastian Bolz
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-30       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.